- published: 23 May 2016
- views: 331
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
BMS' primary R&D sites are located in Lawrence Township (formerly Squibb, near Princeton) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, Japan and Bangalore, India.
Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York. Squibb was known as a vigorous advocate of quality control and high purity standards within the fledgling pharmaceutical industry of his time, at one point self-publishing an alternative to the U.S. Pharmacopeia (Squibb's Ephemeris of Materia Medica) after failing to convince the American Medical Association to incorporate higher purity standards. Mentions of the Materia Medica, Squibb products, and Edward Squibb's opinion on the utility and best method of preparation for various medicants are found in many medical papers of the late 1800s. Squibb Corporation served as a major supplier of medical goods to the Union Army during the United States Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the eastern United States at that time).
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. Sujata’s father always taught her and her siblings that education is something that can never be taken away. That advice brought Sujata to the United States where she earned a graduate degree and eventually started working in cancer research. Dedicating her life to help people in need was a great source of great pride for her father, especially when he became one of the people she was helping. He remained positive throughout his fight with cancer but eventually succumbed to the disease. That experience added to Sujata’s motivation to use her knowledge as best she could to develop medicines quickly for patients ...
Bristol-Myers Squibb CSO Francis Cuss, MB BChir, FRCP, discusses innovation in Immuno-Therapy at this year’s Aspen Ideas Festival in Aspen, Colorado. Read more about the presentation: http://investor.bms.com/news/in-the-know/in-the-know-details/2016/BMS-at-The-Aspen-Ideas-Festival--Immuno-Oncology-in-the-Company-of-World-Class-Innovation/default.aspx Find out more about the Aspen Ideas Festival by the Aspen Institute: http://www.aspenideas.org Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerss... Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
The global pharmaceutical company Bristol-Myers Squibb has announced it is to create highly skilled jobs in a new manufacturing plant in West Dublin. The global pharmaceutical company Bristol-Myers Squibb has announced it is to create highly skilled jobs in a new manufacturing plant in West Dublin. The global pharmaceutical company Bristol-Myers Squibb has announced it is to create highly skilled jobs in a new manufacturing plant in West Dublin. VIDEO: Bristol-Myers Squibb to create 400 jobs in Dublin VIDEO: Bristol-Myers Squibb to c...
At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. Growing up, Colleen’s older brother was the strongest person she knew—and their bond was even stronger. Then he was diagnosed with cancer at age 25. The disease and resulting treatments weakened him to the point where he was unrecognizable to Colleen. At Bristol-Myers Squibb, Colleen is proud of her role in helping the company to ease the pain felt by family members when their loved ones are affected by cancer and other serious diseases.
For Joan, a Bristol-Myers-Squibb employee, hepatitis C (hep C) is much more than a significant global public health challenge – it’s personal. It has played a role in the story of her family, and it was from her family that she learned the importance of “sticking together,” as well as the importance of the work she and the Global Regulatory Sciences team does every day. At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. Explore more employee stories here: http://WorkingTogetherForPatients.com Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: ht...
At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. When Dina was diagnosed with a rare form of cancer, she didn’t go into fight mode right away. Then her doctor recommended a Bristol-Myers Squibb clinical trial. Her appreciation for those who supported her along her journey is matched only by her appreciation for every one of life’s milestones.
Digging into the balance sheet of two drugmaking powerhouses to see which may be a better investment. This podcast was recorded on Dec. 9, 2015. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.faceb...
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Stocks covered: Bristol-Myers Squibb (BMY) MEDNAX (MD) Norwegian Cruise Lines (NCLH) Novo Nordisk (NVO)
Lecture delivered on June 17, 2010. This is the first Distinguished Lecture in Immunology supported by Bristol-Myers Squibb. UC Irvine Institute For Immunology presents Michael D. Cahalan, Ph.D., Professor and Chair Department of Physiology and Biophysics Institute for Immunology University of California, Irvine.
No Show Business do dia 21/06, João Doria Jr. entrevistou o fundador e presidente da Flytour, Eloi D'Avila, e o presidente da Bristol-Myers Squibb, Gaetano Crupi.
Morrey Atkinson, Ph.D., Vice President, Process Sciences, Bristol-Myers Squibb presents on “Challenges Associated with Biomanufacturing of Evolving Portfolios” during his plenary keynote presentation at The Bioprocessing Summit 2016 in Boston. Learn more about the event at http://www.bioprocessingsummit.com
The advantages, challenges and review of opportunities presented by continuous manufacturing and hybrid systems with industry experts Felix Martinez, Process Architect, Bristol-Myers Squibb and Tim Remmert, Executive Director, LB Bohle GmbH. Hosted by Russ Somma, PhD, SommaTech Consulting.
Jibe CEO Joe Essenfeld hosts a panel of talent acquisition thought leaders: Heather Tinguely from Microsoft, Semi Trotto from Bristol-Myers Squibb, and Madeline Laurano from The Brandon Hall Group.
On November 12, 2015, Naiyer A. Rizvi, M.D., director of thoracic oncology and director of immunotherapeutics at Columbia University Medical Center, discussed current immunotherapy treatment options for patients with lung cancer, and how close we are to making these treatments available to more patients. This 45-minute webinar was made possible by the generous support of Bristol-Myers Squibb. Cancer Research Institute's Breakthroughs in Cancer Immunotherapy Webinar Series are offered free to the public and feature informative updates from leaders in cancer immunotherapy, followed by a moderated Q&A;. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.
Dr. Jeremy M. Levin, D.Phil., MB, B.Chir is the Chairman of Ovid Therapeutics, Inc and of Health:Augmented. He previously served as the Chief Executive Officer and President of Teva Pharmaceutical Industries Limited. Prior to joining Teva, Dr. Levin was a member of the senior management team at Bristol-Myers Squibb(BMS), as Senior Vice President of Strategy, Alliances and Transactions.